Status:

COMPLETED

Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)

Lead Sponsor:

Solvay Pharmaceuticals

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

40-85 years

Phase:

PHASE3

Brief Summary

This study aims to assess the analgesic effectiveness and safety of three different doses of a new formulation of Lamaline® versus Dafalgan® Codeine after 10 days administration in subjects with painf...

Eligibility Criteria

Inclusion

  • History of knee (unilateral or bilateral) osteoarthritis for at least 6 months
  • Pain intensity assessed by Visual Analogue Scale ≥ 40 mm
  • Partial functional disability assessed by Lequesne index ≥4 and \< than 12

Exclusion

  • Patient unable to interrupt his/her NSAIDs to participate in the clinical study

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00264225

Start Date

December 1 2005

Last Update

February 20 2008

Active Locations (171)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 43 (171 locations)

1

Site 2

Albi, France

2

Site 3

Andernos-les-Bains, France

3

Site 101

Angers, France

4

Site 103

Angers, France

Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis) | DecenTrialz